Sign in
4

Changes in Ownership

NEKTAR THERAPEUTICS Filed Acc 0000950170-25-113130

Chief R&D Officer sold 485 shares at $30.10 ($14,599)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Zalevsky Jonathan · Chief R&D Officer

Table I: Non-derivative

1 line
Date Transaction Shares Price Value Owned after D/I
2025-09-02 Sale : show line 1 in the form 10b5-1 −485 $30.10 $14,599 19,183 D
Open-market sales · 485 sh · avg $30.10 · $14,599
Loading xslF345X05/ownership.xml…